Patents by Inventor Tommy E. Howard

Tommy E. Howard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Factor VIII mutation repair and tolerance induction
    Patent number: 11083801
    Abstract: Methods of treating hemophilia A in a subject with an F8 gene mutation, wherein the F8 gene is repaired and the resultant repaired gene, upon expression, confers improved coagulation functionality to the encoded FVIII protein of the subject compared to the non-repaired F8 gene. The invention also includes methods of inducing immune tolerance to a FVIII replacement product ((r)FVIII) in a subject having a FVIII deficiency, wherein the F8 gene mutation is repaired and the repaired gene, upon expression, provides for the induction of immune tolerance to an administered replacement FVIII protein product. The invention also includes isolated nucleic acids, vectors, recombinant viruses, cells, and pharmaceutical compositions to repair the F8 gene.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: August 10, 2021
    Assignees: Haplomics, Inc., The Regents of the University of California, The United States Government Represented by the Departrment of Veteran Affairs
    Inventors: Vincent Laterza, Tommy E. Howard
  • FACTOR VIII MUTATION REPAIR AND TOLERANCE INDUCTION
    Publication number: 20190351073
    Abstract: Methods of treating hemophilia A in a subject with an F8 gene mutation, wherein the F8 gene is repaired and the resultant repaired gene, upon expression, confers improved coagulation functionality to the encoded FVIII protein of the subject compared to the non-repaired F8 gene. The invention also includes methods of inducing immune tolerance to a FVIII replacement product ((r)FVIII) in a subject having a FVIII deficiency, wherein the F8 gene mutation is repaired and the repaired gene, upon expression, provides for the induction of immune tolerance to an administered replacement FVIII protein product. The invention also includes isolated nucleic acids, vectors, recombinant viruses, cells, and pharmaceutical compositions to repair the F8 gene.
    Type: Application
    Filed: April 26, 2019
    Publication date: November 21, 2019
    Applicants: Haplomics, Inc., The Regents of the University of California, The United States Government as respresented by the Department of Veterans Affairs
    Inventors: Vincent LATERZA, Tommy E. HOWARD
  • Factor VIII mutation repair and tolerance induction
    Patent number: 10272163
    Abstract: Methods of treating hemophilia A in a subject with an F8 gene mutation, wherein the F8 gene is repaired and the resultant repaired gene, upon expression, confers improved coagulation functionality to the encoded FVIII protein of the subject compared to the non-repaired F8 gene. The invention also includes methods of inducing immune tolerance to a FVIII replacement product ((r)FVIII) in a subject having a FVIII deficiency, wherein the F8 gene mutation is repaired and the repaired gene, upon expression, provides for the induction of immune tolerance to an administered replacement FVIII protein product. The invention also includes isolated nucleic acids, vectors, recombinant viruses, cells, and pharmaceutical compositions to repair the F8 gene.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: April 30, 2019
    Assignees: The Regents of the University of California, The United States of America Represented by the Department of Veterans Affairs, Haplomics, Inc.
    Inventors: Vincent Laterza, Tommy E. Howard
  • PREDICTING AND REDUCING ALLOIMMUNOGENICITY OF PROTEIN THERAPEUTICS
    Publication number: 20160038570
    Abstract: Methods of predicting the immunogenicity of a therapeutic protein in a subject are provided and the use of this method in selecting a protein for replacement therapy having the fewest immunogenic epitopes. The method is demonstrated by reference to ADAMTS13. Isolated allelic variants of ADAMTS13 that contribute to the variability in risk for both arterial and venous thrombotic disease development are provided. The allelic variants are identified as single nucleotide polymorphisms (ns-SNPs) in the ADAMTS13 gene, which result in haplotypes identified as H1 to H14. A method for improving outcomes of transfusions/transplant products is also provided by selection of haplotype matched therapeutics.
    Type: Application
    Filed: September 28, 2015
    Publication date: February 11, 2016
    Inventor: Tommy E. HOWARD
  • COMPOSITIONS AND METHODS FOR IMMUNE TOLERANCE INDUCTION TO FACTOR VIII REPLACEMENT THERAPIES IN SUBJECTS WITH HEMOPHILIA A
    Publication number: 20160038575
    Abstract: This disclosure relates to tolerance inducing peptide (TIP) derived from the amino acid reference locus (AARL) within a FVIII replacement product (FVIIIrp) based on the differences between the expression product of a subject's F8 gene (sFVIII) and the FVIIIrp to provide tolerance induction before, during, and/or after a FVIII replacement therapy in a subject suffering from Hemophila A. Methods of deriving, making, and using the TIP are also disclosed. In some embodiments, the TIP is associated with a nanoparticle, e.g., PLGA or PLGA-PEMA nanoparticle.
    Type: Application
    Filed: March 17, 2014
    Publication date: February 11, 2016
    Inventors: Tommy E. HOWARD, Vincent LA TERZA
  • FACTOR VIII MUTATION REPAIR AND TOLERANCE INDUCTION
    Publication number: 20150306250
    Abstract: Methods of treating hemophilia A in a subject with an F8 gene mutation, wherein the F8 gene is repaired and the resultant repaired gene, upon expression, confers improved coagulation functionality to the encoded FVIII protein of the subject compared to the non-repaired F8 gene. The invention also includes methods of inducing immune tolerance to a FVIII replacement product ((r)FVIII) in a subject having a FVIII deficiency, wherein the F8 gene mutation is repaired and the repaired gene, upon expression, provides for the induction of immune tolerance to an administered replacement FVIII protein product. The invention also includes isolated nucleic acids, vectors, recombinant viruses, cells, and pharmaceutical compositions to repair the F8 gene.
    Type: Application
    Filed: December 6, 2013
    Publication date: October 29, 2015
    Inventors: Vincent LATERZA, Tommy E. HOWARD
  • Allelic Variants of Human Factor VIII
    Publication number: 20100256062
    Abstract: Disclosed are compositions and methods related to Factor VIII.
    Type: Application
    Filed: December 6, 2005
    Publication date: October 7, 2010
    Inventors: Tommy E. Howard, Vincent La Terza